BR112021019669A2 - Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno - Google Patents

Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno

Info

Publication number
BR112021019669A2
BR112021019669A2 BR112021019669A BR112021019669A BR112021019669A2 BR 112021019669 A2 BR112021019669 A2 BR 112021019669A2 BR 112021019669 A BR112021019669 A BR 112021019669A BR 112021019669 A BR112021019669 A BR 112021019669A BR 112021019669 A2 BR112021019669 A2 BR 112021019669A2
Authority
BR
Brazil
Prior art keywords
compound
disorder
treating
medicine
production
Prior art date
Application number
BR112021019669A
Other languages
English (en)
Inventor
Charles Good Andrew
J Philipps Andrew
A Henderson James
Minsheng He
Original Assignee
C4 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C4 Therapeutics Inc filed Critical C4 Therapeutics Inc
Publication of BR112021019669A2 publication Critical patent/BR112021019669A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno. são descritos ligantes tricíclicos de cereblon para a degradação de ikaros ou aiolos pela via da ubiquitina-proteassoma para aplicações terapêuticas.
BR112021019669A 2019-04-12 2020-04-10 Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno BR112021019669A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833107P 2019-04-12 2019-04-12
PCT/US2020/027678 WO2020210630A1 (en) 2019-04-12 2020-04-10 Tricyclic degraders of ikaros and aiolos

Publications (1)

Publication Number Publication Date
BR112021019669A2 true BR112021019669A2 (pt) 2021-12-07

Family

ID=72750851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019669A BR112021019669A2 (pt) 2019-04-12 2020-04-10 Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno

Country Status (14)

Country Link
US (2) US11407732B1 (pt)
EP (1) EP3953332A4 (pt)
JP (1) JP2022527216A (pt)
KR (1) KR20210152515A (pt)
CN (1) CN113677664A (pt)
AU (1) AU2020272978A1 (pt)
BR (1) BR112021019669A2 (pt)
CA (1) CA3130469A1 (pt)
EA (1) EA202192738A1 (pt)
IL (1) IL287116A (pt)
MA (1) MA55628A (pt)
MX (1) MX2021012524A (pt)
SG (1) SG11202109024YA (pt)
WO (1) WO2020210630A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
JP7323603B2 (ja) * 2018-09-07 2023-08-08 メッドシャイン ディスカバリー インコーポレイテッド 三環式縮合フラン置換ピペリジンジオン系化合物
US11807620B2 (en) 2020-02-21 2023-11-07 Plexium, Inc. Quinazolinone compounds and related compounds
JP2023538520A (ja) * 2020-08-07 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ又はａｉｏｌｏｓによって媒介される障害に対する有利な治療法
KR20230107569A (ko) * 2020-10-14 2023-07-17 씨4 테라퓨틱스, 인코포레이티드 Ikzf2 또는 ikzf4의 분해를 위한 트리시클릭 리간드
JP2023545507A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 標的化タンパク質を分解する三環式ヘテロ二官能性化合物
IL308219A (en) 2021-05-05 2024-01-01 Biogen Ma Inc Compounds to Target Broton Tyrosine Kinase Degradation
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
EP4366834A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
EP4367113A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
CN117940415A (zh) * 2021-08-27 2024-04-26 杭州格博生物医药有限公司 异吲哚啉酮化合物及其用途
WO2023059792A1 (en) * 2021-10-06 2023-04-13 C4 Thrapeutics, Inc. Coronavirus non-structural protein 3 degrading compounds
CN118201923A (zh) * 2021-10-15 2024-06-14 海南先声再明医药股份有限公司 三环类化合物
WO2023154417A1 (en) * 2022-02-09 2023-08-17 C4 Therapeutics, Inc. Morphic forms of cft7455 and methods of manufacture thereof
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN116120261B (zh) * 2022-11-30 2024-01-23 浙大宁波理工学院 一种3-[（4-磺胺哌嗪-1-基）甲基]苯甲酸类化合物的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6504034B2 (en) * 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
BRPI0716092A2 (pt) 2006-08-30 2013-09-17 Celgene Corp composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
UA95975C2 (ru) 2006-09-15 2011-09-26 Селджин Корпорэйшн N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
US8153659B2 (en) 2007-03-20 2012-04-10 Celgene Corporation 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
BRPI0817525A2 (pt) 2007-09-26 2014-11-18 Celgene Corp Composto, composição farmacêutica, e, metódo de tratamento, controle ou prevenção de uma doença ou distúrbio.
US20090298882A1 (en) 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
NZ592425A (en) 2008-10-29 2013-04-26 Celgene Corp Isoindoline compounds for use in the treatment of cancer
WO2012175481A1 (en) 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
CN104736569A (zh) 2012-01-12 2015-06-24 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
EA201691144A1 (ru) 2013-12-06 2016-11-30 Селджин Корпорейшн Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка
CN111662226B (zh) * 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
EP3404024B1 (en) 2016-01-14 2020-11-18 Kangpu Biopharmaceuticals, Ltd. Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
CN110049765B (zh) 2016-12-16 2022-02-01 康朴生物医药技术（上海）有限公司 一种组合、其应用及治疗方法
CN110248662B (zh) 2017-02-13 2022-08-16 康朴生物医药技术（上海）有限公司 一种治疗前列腺癌的组合、药物组合物及治疗方法
CA3052516C (en) 2017-02-28 2022-08-16 Kangpu Biopharmaceuticals, Ltd. An isoindoline derivative, a pharmaceutical composition and use thereof
BR112020000442A2 (pt) 2017-07-10 2020-07-21 Celgene Corporation compostos antiproliferativos e métodos de uso dos mesmos
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
US10905684B2 (en) 2018-06-13 2021-02-02 Biotheryx, Inc. Aminoamide compounds
KR20210027395A (ko) 2018-06-29 2021-03-10 다나-파버 캔서 인스티튜트 인크. 면역조절 화합물
CA3102217A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Bispecific degraders
EP3813834A4 (en) 2018-06-29 2022-03-09 Dana Farber Cancer Institute, Inc. NEW CRBN MODULATORS
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
CR20210001A (es) 2018-07-10 2021-04-19 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2)
US20220388978A1 (en) 2019-08-27 2022-12-08 Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
WO2021127586A1 (en) 2019-12-20 2021-06-24 Calico Life Sciences Llc Protein tyrosine phosphatase degraders and methods of use thereof

Also Published As

Publication number Publication date
EP3953332A4 (en) 2023-06-14
CN113677664A (zh) 2021-11-19
JP2022527216A (ja) 2022-05-31
CA3130469A1 (en) 2020-10-15
AU2020272978A1 (en) 2021-09-16
EP3953332A1 (en) 2022-02-16
EA202192738A1 (ru) 2022-03-17
IL287116A (en) 2021-12-01
KR20210152515A (ko) 2021-12-15
US20230082430A1 (en) 2023-03-16
MX2021012524A (es) 2021-11-12
US11407732B1 (en) 2022-08-09
SG11202109024YA (en) 2021-09-29
MA55628A (fr) 2022-02-16
WO2020210630A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
BR112021019669A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno
CR20220240A (es) Inhibidores de ras
MX2022005360A (es) Inhibidores de ras.
MX2021007468A (es) Compuestos que participan en la union cooperativa y usos de los mismos.
MX2022005359A (es) Inhibidores de ras.
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
BR112017019738A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112019006853A2 (pt) composição farmacêutica líquida
BR112019005328A2 (pt) composição farmacêutica líquida
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112022012514A2 (pt) Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas
BR112021015616A2 (pt) Ligantes de pseudoquinase tyk2
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro
MX2022009762A (es) Moduladores del purinorreceptor 3 p2x (p2x3).
CO2022005082A2 (es) Inhibidores del fxia y método de preparación de los mismos y aplicación farmacéutica de los mismos
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
BR112022000855A2 (pt) Moduladores de nlrp3
CO2022014499A2 (es) Moduladores de nlrp3
MX2018013729A (es) Forma cristalina nueva de dapagliflozina y metodo de preparacion y uso de la misma.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение